"Tositumomab and Iodine I 131 TositumomabPTNCI" . _:b720092 . _:b720093 . . _:b720092 . "Therapeutic or Preventive Procedure"^^ . "tositumomabPTNCI-GLOSSCDR0000367410" . "tositumomab and iodine I 131 tositumomabPTNCI-GLOSSCDR0000588694" . "CL378645"^^ . _:b720092 . _:b720092 . _:b720093 . "Tositumomab and Iodine I 131 Tositumomab"^^ . "Tositumomab_I-131_Tositumomab"^^ . "Tositumomab and Iodine I 131 Tositumomab"^^ . _:b720093 . "Bexxar regimenPTNCI-GLOSSCDR0000367411" . "588881"^^ . "C72672"^^ . "588881"^^ . "A murine IgG2a lambda monoclonal antibody, both unradiolabeled and radiolabeled with iodine I 131, directed against the human B cell-specific surface antigen CD20. Tositumomab binds to CD20, resulting in complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and apoptosis in B cells expressing CD20; in addition to the antibody-mediated cytotoxicity, iodine I 131 tositumomab delivers cytotoxic ionizing radiation specifically to CD20-expressing B cells. In a two-step therapeutic regimen, a predose of unradiolabeled tositumomab is administered first followed by the administration of a dosimetric dose of iodine I 131 tositumomab; 7-14 days later, a therapeutic dose of iodine I 131 tositumomab is administered. The predose of unradiolabeled tositumomab binds to nontumor B cells, increasing the terminal half-life of radiolabeled antibody while protecting nontumor B cells from radiolabeled antibody-mediated radiocytotoxicity.NCI" . "Bexxar TherapySYNCI" . . "A combination of monoclonal antibodies used to treat certain types of non-Hodgkin lymphoma. The monoclonal antibody tositumomab is given with iodine I 131 tositumomab (a form of tositumomab that has been chemically changed by adding radioactive iodine). Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells.NCI-GLOSS" . _:b720093 . "Bexxar Therapeutic RegimenSYNCI" .